NCT06609850Recruiting
The Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular Carcinoma
The Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular Carcinoma: a Multicenter Randomized Control Study
Source: ClinicalTrials.gov · Last updated 3 Dec 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Studies have shown that combination therapy of TACE with Lenvatinib could achieve better survival outcomes than TACE alone for hepatocellular carcinoma (HCC) at BCLC B stage. However, whether patients could benefit from the ablation for intermediate recurrent HCC (RHCC) is still need high quality clinical evidence. This study is to evaluate the efficacy of ablation combined with TACE and Lenvatinib for the intermediate-stage RHCC.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 116 (estimated)
- First submitted
- 20 Sept 2024
- Start date
- 1 Oct 2024
- Primary completion date
- 1 Oct 2026
- Lead sponsor
- Sun Yat-sen University
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT06609850
What you commit to
- Study type: Interventional
- Planned participants: 116
- From 1 Oct 2024 to the primary completion date, 1 Oct 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Age
- under 18 years or over 75 years of age;
Other
- primary intermediate-stage HCC;
- RHCC with more than six tumors, or single RHCC
- (5) RHCC \>5cm; (6) extrahepatic metastasis; (7) macrovascular tumor thrombus;
Who the study is looking for
- 18-75 years;
- RHCC diagnosed by imaging;
- intermediate-stage RHCC (two to three lesions which at least one was \>3 cm in size or more than three tumors);
- the tumor number was no more than six, and the maximum tumor diameter was ≤5 cm;
- absence of extrahepatic metastasis or macrovascular invasion;
- Child-Pugh class A or B;
- TACE as initial treatment after tumor recurrence and showed no tumor progression after TACE.
- life expectance \>3 months;
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Chinese PLA General Hospital Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.